Evidence map›Paper›PMID 29644482›Full record

ArticleClinical and experimental medicine2018

Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis.

Neide Tomimura Costa, Bruna Miglioranza Scavuzzi, Tatiana Mayumi Veiga Iriyoda, Marcell Alysson Batisti Lozovoy, Daniela Frizon Alfieri, Fabiano Aparecido de Medeiros, Marcelo Cândido de Sá, Pâmela Lonardoni Micheletti, Bruno Alexandre Sekiguchi, Edna Maria Vissoci Reiche and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. A systematic review and meta-analysis of circulating adhesion molecules in rheumatoid arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Nitric Oxide Synthases in Rheumatoid Arthritis.Molecules (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Neide Tomimura CostaLaboratory of Research in Applied Immunology, University of Londrina, Londrina, Paraná, Brazil.
Bruna Miglioranza ScavuzziLaboratory of Research in Applied Immunology, University of Londrina, Londrina, Paraná, Brazil.
Tatiana Mayumi Veiga IriyodaDepartment of Rheumatology - PUC, Pontifícia Universidade Católica, Londrina, Paraná, Brazil.
Marcell Alysson Batisti LozovoyDepartment of Clinical Pathology, Clinical Analysis and Toxicology - University of Londrina, Robert Koch Avenue No. 60 Bairro Cervejaria, Londrina, Paraná, CEP: 86038-440, Brazil.
Daniela Frizon AlfieriLaboratory of Research in Applied Immunology, University of Londrina, Londrina, Paraná, Brazil.
Fabiano Aparecido de MedeirosPost Graduate Program in Clinical and Laboratory Pathophysiology, University of Londrina, Londrina, Paraná, Brazil.
Marcelo Cândido de SáPost Graduate Program in Clinical and Laboratory Pathophysiology, University of Londrina, Londrina, Paraná, Brazil.
Pâmela Lonardoni MichelettiPost Graduate Program in Clinical and Laboratory Pathophysiology, University of Londrina, Londrina, Paraná, Brazil.
Bruno Alexandre SekiguchiLaboratory of Research in Applied Immunology, University of Londrina, Londrina, Paraná, Brazil.
Edna Maria Vissoci ReicheDepartment of Clinical Pathology, Clinical Analysis and Toxicology - University of Londrina, Robert Koch Avenue No. 60 Bairro Cervejaria, Londrina, Paraná, CEP: 86038-440, Brazil.
Michael MaesIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia.
Andréa Name Colado SimãoDepartment of Clinical Pathology, Clinical Analysis and Toxicology - University of Londrina, Robert Koch Avenue No. 60 Bairro Cervejaria, Londrina, Paraná, CEP: 86038-440, Brazil. deianame@yahoo.com.br.ORCID http://orcid.org/0000-0002-2073-6782
Isaias DichiDepartment of Internal Medicine, University of Londrina, Londrina, Paraná, Brazil.
Universidade Estadual de Londrina · BRDeakin University · AUPontifícia Universidade Católica do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress plays a role in the pathophysiology of rheumatoid arthritis (RA). The aim of the present study was to verify the influence of metabolic syndrome (MetS) and disease-modifying antirheumatic drugs on nitrosative and oxidative biomarkers in patients with RA. A total of 177 patients with RA and 150 healthy volunteers participated in this study, which measured lipid hydroperoxides, advanced oxidation protein products (AOPP), nitric oxide metabolites (NOx), carbonyl protein, total radical-trapping antioxidant parameter (TRAP), uric acid (UA), and C-reactive protein (CRP). NOx and the NOx/TRAP ratio were significantly increased in RA, while no significant differences in lipid hydroperoxides, AOPP, UA, and TRAP levels were found between both groups. Treatment with leflunomide was associated with increased levels of carbonyl protein, and lowered levels in TRAP and UA, while the NOx/TRAP ratio further increased. NOx and the NOx/TRAP ratio were significantly higher in women than in men, while TRAP and UA were significantly lower in women. MetS was accompanied by increased AOPP and UA levels. RA was best predicted by increased NOx/TRAP ratio, CRP, and BMI. In conclusion, our data demonstrated that NOx and NOx/TRAP are strongly associated with RA physiopathology. Our findings suggest that inhibition of iNOS may become an interesting therapeutic approach for the treatment of RA. In addition, the presence of MetS and a decrease in levels of UA by leflunomide favor redox imbalance in RA patients. More studies are needed to evaluate the impact of antioxidant capacity reduction on RA progression.

Indexed as

AdolescentAdultAdvanced Oxidation Protein ProductsAgedAntirheumatic AgentsArthritis, RheumatoidCase-Control StudiesC-Reactive ProteinDisease ProgressionFemaleGene ExpressionHumansIsoxazolesLeflunomideLipid PeroxidesMaleAdvanced Oxidation Protein ProductsAntirheumatic AgentsC-Reactive ProteinIsoxazolesLeflunomideLipid PeroxidesNitric OxideNitric Oxide Synthase Type IINOS2 protein, humanUric AcidLeflunomideMetabolic syndromeNitrosative stressOxidative stressRheumatoid arthritis

Identifiers

PMID29644482
OpenAlexW2797388110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.